Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner

Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner

As one of the hallmarks of cancer, metabolic reprogramming leads to cancer progression, and targeting glycolytic enzymes could be useful strategies for cancer therapy. By screening a small molecule library consisting of 1320 FDA-approved drugs, we found that penfluridol, an antipsychotic drug used t...

Full description

Bibliographic Details
Main Authors: Cancan Zheng, Xiaomei Yu, Yiyao Liang, Yidong Zhu, Yan He, Long Liao, Dingkang Wang, Yanming Yang, Xingfeng Yin, Ang Li, Qingyu He, Bin Li
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Drug repurposing
Metabolic reprogramming
Glycolysis
PFKL
DARTS technology
Esophageal cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S221138352100349X

Internet

http://www.sciencedirect.com/science/article/pii/S221138352100349X

Similar Items